IF isotretinoin (10 mg/kg/day, oral gavage) is administered for 8 weeks to 24-month-old C57BL/6 mice preceded by a 2-week anti-inflammatory preconditioning phase using a JAK1/2 inhibitor (ruxolitinib, 30 mg/kg/day oral gavage) to arrest ongoing inflammation-driven lamin-B1 degradation in thymic epithelial cells (TECs),
THEN a synergistic ≥2-fold expansion of functional cTEC (MHCIIhiUEA-1−) and mTEC (MHCIIhiUEA-1+AIRE+) populations, ≥50% restoration of FOXN1 protein in sorted TECs, ≥30% increase in thymic mass, and ≥40% rise in TREC+ naive CD4+CD62L+CD44− T cells in peripheral blood versus aged vehicle controls will be observed at week 10 — outcomes unachievable by isotretinoin monotherapy —
BECAUSE the following causal chain operates sequentially:
-
Chronic thymic inflammation in aged mice drives progressive, cell-type-specific lamin-B1 loss in TECs, causing disrupted corticomedullary architecture, loss of TEC subset composition, impaired thymopoiesis, and a perivasculitis-like inflammatory microenvironment — establishing that nuclear lamina structural damage is an upstream, accumulated lesion in aged TECs, not merely a correlate of FOXN1 decline. (Lamin-B1 in TEC aging)[https://doi.org/10.1111/acel.12952]
-
Lamin-B1 depletion repositions genes including Foxn1 toward lamina-associated repressive domains (LADs), closing chromatin accessibility at RAR/RXR response element–containing regulatory regions of the Foxn1 promoter/enhancer. This means that even if retinoic acid receptors are pharmacologically activated by isotretinoin, they cannot access a Foxn1 loc





























